Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L21 is a structural component of the large (60S) subunit of cytoplasmic ribosomes, organelles responsible for catalyzing protein synthesis in cells[2][3][1]. RPL21 belongs to the L21E family of ribosomal proteins and primarily functions in translation as part of the ribosome. Beyond its canonical role, RPL21 (also known as eL21) demonstrates extra-ribosomal functions; for example, it interacts with the lysine methyltransferase SMYD2, influencing cell proliferation and potentially contributing to oncogenic processes when dysregulated[1][6]. Mutations in RPL21 are causative for hereditary hypotrichosis simplex, a non-syndromic form of hair loss[1][2][3][4]. There are currently no drugs known to directly target RPL21, and its use as a drug target is not established; rather, its significance is primarily in fundamental biology and as a disease gene in specific hereditary and potentially oncogenic contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L21 (RPL21).